Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada has successfully met the primary endpoint in the Phase III US clinical trials with its intravenous Alpha-1 Antitrypsin.
Subscribe to our email newsletter
Alpha-1 Antitrypsin (AAT) is used to treat hereditary AAT deficiency which leads to Congenital Emphysema.
David Tsur, CEO of Kamada, said: “The company’s intravenous Alpha-1 Antitrypsin (AAT) is the only ready-to-use AAT product that does not require reconstitution before use. Concurrently, Kamada is developing the next generation AAT for various indications, to be delivered by inhalation, directly to the lungs.”